ACADIA Pharmaceuticals Inc. Q3 2026 Earnings Recap

Acadia reported higher third-quarter revenue and raised DAYBUE guidance, while its Phase II RADIANT study narrowly missed statistical significance on the primary endpoint. Shares fell 1.1% after earnings, a roughly flat reaction.

Key Takeaways

• Total revenue was $342 million, up 22% year over year on an adjusted basis.
• DAYBUE sales reached a record $140 million, up 39%; management raised 2026 DAYBUE guidance.
• NUPLAZID sales were $202 million, up 12% on an adjusted basis, with growth driven largely by patient demand through volume.
• RADIANT’s Phase II portion narrowly missed statistical significance on its primary endpoint; Acadia plans to focus the Phase III program on the 60-milligram dose.
• Acadia expects ILLUMERA Phase II results in LBD psychosis in the fourth quarter of 2027, while an additional NORLIGHT readout is now expected in the second half of 2027.